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Abstract
The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple myeloma. However, long-term
remissions are difficult to achieve, andmyeloma cells often develop secondary resistance to proteasome inhibitors. We
recently demonstrated that the extraordinary sensitivity of myeloma cells toward bortezomib is dependent on their
extensive immunoglobulin synthesis, thereby triggering the terminal unfolded protein response (UPR). Here, we inves-
tigated whether verapamil, an inhibitor of the multidrug resistance (MDR) gene product, can enhance the cytotoxicity of
bortezomib. The combination of bortezomib and verapamil synergistically decreased the viability of myeloma cells by
inducing cell death. Importantly, bortezomib-mediated activation ofmajorUPRcomponentswas enhancedby verapamil.
The combination of bortezomib and verapamil resulted in caspase activation followed by poly(ADP-ribose) polymerase
cleavage, whereas nuclear factor κB (NF-κB) activity declined inmyeloma cells. Also, we found reduced immunoglobulin
G secretion along with increased amounts of ubiquitinylated proteins within insoluble fractions of myeloma cells when
using the combination treatment. Verapamil markedly induced reactive oxygen species production and autophagic-
like processes. Furthermore, verapamil decreased MDR1 expression. We conclude that verapamil increased the anti-
myeloma effect of bortezomib by enhancing ER stress signals along with NF-κB inhibition, leading to cell death. Thus,
the combination of bortezomib with verapamil may improve the efficacy of proteasome inhibitory therapy.
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Introduction
Multiple myeloma, a virtually incurable plasma cell neoplasia, is charac-
terized by the production of large amounts of monoclonal immuno-
globulins and accounts for approximately 10% of all hematologic
cancers [1]. Existing therapeutic strategies such as high-dose chemo-
therapy followed by hematopoietic stem cell transplantation prolong
survival of multiple myeloma patients but rarely induce long-lasting
complete remissions. These treatments are also associated with severe
adverse effects [2].
The proteasome inhibitor bortezomib (Velcade) markedly improved
the treatment options for patients with relapsed multiple myeloma by
inducing apoptosis in myeloma cells [3]. The dipeptidyl boronic acid
derivative bortezomib is a highly selective and reversible inhibitor of the
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26S proteasome, a multienzyme complex present in all eukaryotic cells.
The 26S proteasome degrades supernumerous, defective, or misfolded
proteins, which are targeted for proteasomal degradation by polyubi-
quitinylation. In addition, it plays a fundamental role in cellular homeo-
stasis as a critical regulator of cell proliferation and apoptosis [4,5].
The antitumor effect of bortezomib has been demonstrated in vitro
and in vivo for various types of cancers. Myeloma cells seem to be ex-
ceptionally sensitive. Even the growth of chemotherapy-resistant mye-
loma cell lines was inhibited by bortezomib treatment [6]. Bortezomib
exerts its effect through multiple pathways that target both the tumor
cell and its environment. The cytotoxic effect of bortezomib seems to
be partially due to the inhibition of the antiapoptotic transcription
factor nuclear factor κB (NF-κB). Bortezomib stabilizes endogenous
inhibitor of kappa B alpha (IκBα) that sequesters NF-κB in the cyto-
plasm and prevents transcriptional activation of NF-κB target genes [7].
Importantly, we and others demonstrated that bortezomib-induced
apoptosis is caused by excessive endoplasmic reticulum (ER) stress, ac-
tivating the terminal unfolded protein response (UPR), especially in cells
with extensive synthesis of secretory proteins [8–11].
The UPR is a signaling pathway from the ER to the nucleus triggered
by the accumulation of misfolded proteins in the ER lumen and is es-
sential for plasma cell differentiation and survival. The UPR includes
three mechanisms to handle the vast increase of unfolded proteins: tran-
scriptional induction of target genes enhancing protein folding, general
translational repression, and ER-associated degradation to eliminate
misfolded proteins. However, overwhelming ER stress activates the ter-
minal UPR, leading to apoptosis [12,13].
Somemyeloma patients are resistant or become refractory to ongoing
bortezomib treatment [14]. To improve the efficacy of proteasome
inhibitor–based treatments and to overcome primary and secondary
resistance, drugs augmenting the antitumor properties of bortezomib
inmyeloma cells are required.We identified the L-type calcium channel
antagonist verapamil (Isoptin; Abbott,Wiesbaden, Germany), clinically
used for the treatment of cardiac arrythmias, hypertension, and, most
recently, for cluster headaches, as a promising combination partner with
bortezomib. The phenylalkylamine derivative verapamil potently inhib-
its the influx of calcium ions into cells [15]. Further, in drug-resistant
leukemic cell lines, verapamil interfered with the multidrug resistance
(MDR)–based drug elimination by decreasing P-glycoprotein (P-gp)
expression [16]. In this study, we observed that verapamil enhanced
the proapoptotic effect of bortezomib. Increased cell death was associ-
ated with induction of terminal UPR and autophagy; however, a causal
link and the molecular mechanisms require further investigation.
Materials and Methods
Antibodies
For immunoblot analysis, the following primary antibodies were
used: mouse monoclonal anti-GRP78 (BiP), rabbit polyclonal anti-
GRP94, and mouse monoclonal anti–poly(ADP-ribose) polymerase
(PARP; BD Pharmingen, Heidelberg, Germany); mouse monoclonal
anti–Bcl-2, rabbit polyclonal anti-Bax, rabbit polyclonal anti-Bim,
mouse monoclonal anti-caspase 9, rabbit polyclonal anti-CHOP, rabbit
polyclonal anti–p-eIF2a, mouse monoclonal anti-Hsp70, rabbit poly-
clonal anti–inositol-requiring transmembrane kinase/endonuclease 1α
(IRE1α), rabbit polyclonal anti–p–PKR-like ER kinase (PERK), and
rabbit polyclonal anti–X-box binding protein (XBP-1; all from Santa
Cruz Biotechnology, Santa Cruz, CA); rabbit polyclonal anti-(active)
Jun N-terminal kinase (JNK) and rabbit polyclonal anti–phospho-
p38 (Promega,Madison,WI); rabbit polyclonal anti-actin (Sigma, Tauf-
kirchen, Germany); mouse monoclonal anti-ATF4 (Abnova GmbH,
Heidelberg, Germany); mouse monoclonal anti-ATF6α (Acris, Her-
ford, Germany); rabbit polyclonal anti-LC3 (MBL, Nagoya, Japan);
rabbit polyclonal anti-LMP7 (Novus Biologicals, Littleton, CO); rabbit
polyclonal anti-PSMB5 (Abcam, Cambridge, UK); and mouse mono-
clonal anti-ubiquitin (Zymed Laboratories, Invitrogen Corporation,
Carlsbad, CA). As secondary antibodies, we used HRP-conjugated
goat anti-mouse immunoglobulinG (IgG), goat antirabbit IgG ( Jackson
Immunoresearch Laboratories, Inc, West Grove, PA), and donkey anti-
goat IgG (Santa Cruz Biotechnology). For flow cytometry, we used
mouse anti-human CD243 (MDR1) AlexaFluor 647–conjugated anti-
body (Serotec, Düsseldorf, Germany). ELISA was performed with goat
anti-human IgG (Jackson Immunoresearch Laboratories, Inc) and HRP-
conjugated goat anti-human IgG (Southern Biotech, Birmingham, AL).
Reagents
Bortezomib (PS-341, Velcade; Janssen-Cilag, Neuss, Germany) and
verapamil (Isoptin, Abbott) were obtained from the University Hospital
Pharmacy, Erlangen. PS-1145 dihydrochloride (Sigma-Aldrich).
Cell Lines and Culture Conditions
Cell lines used in this study were grown in RPMI 1640medium sup-
plemented with 50 U/ml penicillin, 50 μg/ml streptomycin, 1 mM
sodium pyruvate, 2 mM L-glutamine, 50 μM β-mercaptoethanol,
10% fetal bovine serum for RPMI 8226 cells (myeloma), ARH 77 cells
(plasma cell leukemia), and 20% bovine serum for JK-6L cells (mye-
loma) [9]. Cells were maintained at 37°C in a humidified incubator
containing 5% CO2. The medium and all supplements were obtained
from Gibco (Invitrogen, Karlsruhe, Germany).
Viability Assay
Cells (1 × 105) were treated with 10 nM bortezomib and/or 70 μM
verapamil for 16 hours and incubated for another 4 hours with Alamar-
Blue (BioSource International, Inc, Camarillo, CA). Activity of the
mitochondrial dehydrogenase results in conversion of the coloring,
which was followed by measurement of the absorption using a spectro-
photometer (SpectraMax 190; Molecular Devices, Sunnyvale, CA).
Flow Cytometric Analysis
Surface staining was performed as described [17]. The cells were ana-
lyzed by flow cytometry using a FACS Calibur (BD Biosciences, San
Jose, CA). Data analyses were performed using the Cell Quest software
(BD Biosciences).
Cell Death Analysis
Cells (1 × 105) were treated with 10 nM bortezomib and/or 70 μM
verapamil for 16 hours. Fifty micromolars of the broad-range caspase
inhibitor zVAD-FMK (Alexis Biochemicals, San Diego, CA) was used
to block caspase activation. Staining with annexin V–fluorescein iso-
thiocyanate (FITC; Genethor, Berlin, Germany) and propidium iodide
(Sigma-Aldrich) was performed as described [18].
Caspase 3/7 Assay
Cells (5 × 104) were treated with 10 nM bortezomib and/or 70 μM
verapamil for 16 hours. Caspase 3/7 activity was measured with the
caspase-Glo-3/7 assay (Promega) according to the manufacturer’s in-
structions. Luminescence was measured using the 96-well plate reader
SpectraMax 190 (Molecular Devices, Sunnyvale, CA).
Neoplasia Vol. 12, No. 7, 2010 Verapamil Enhances Bortezomib-Induced ER-Stress Meister et al. 551
Proteasomal Activity
Cells (2 × 104) were treated with 10 nM bortezomib and/or 70 μM
verapamil for 8 hours. The chymotrypsin-like activity was detected
using the luminogenic proteasome substrate-based Proteasome-Glo
Chymotrypsin-Like Cell-Based Assay Kit (Promega) according to
the manufacturer’s instructions. Luminescence was measured using
the 96-well plate reader SpectraMax 190 (Molecular Devices, Sunny-
vale, CA).
Measurement of the Mitochondrial Potential
The fluorescent dye 3,3-dihexyloxacarbocyanine iodide (DiOC6;
Sigma-Aldrich) was used to reveal disruption of themitochondrial trans-
membrane potential (ΔΨm). For measurement, cells (1 × 10
5) were
treated with 40 nM bortezomib and/or 70 μM verapamil for 10 hours.
Afterward, cells were incubated with 120 nM DiOC6 dye for 20 min-
utes at 37°C in the dark. Stained cells were resuspended in 20 ng/ml
isotonic propidium iodide solution to exclude dead cells and were ana-
lyzed by flow cytometry (Epics XL; Coulter Co, Miami, FL).
Reactive Oxygen Species Production
Cells (1 × 105) were treated with 40 nM bortezomib and/or
70 μM verapamil and incubated for 2 hours with 10 μM 2′,7′-
dichlorofluorescein diacetate (DCFH; Sigma-Aldrich) at 37°C. DCFH
penetrates the cells and is in turn oxidized to DCF in the presence of
reactive oxygen species (ROS). To eliminate ROS production, cells were
preincubated with 10 mM N -acetylcysteine (NAC; Sigma-Aldrich)
1 hour before adding the inhibitors. H2O2 (400 μM) was selected as
a donor to get maximal DCF intensity. DCF fluorescence intensity was
determined by flow cytometric analysis (Epics XL; Coulter Co).
Immunoblot Analysis
Cells (2 × 106) were treated with 10 nM bortezomib and/or 70 μM
verapamil for up to 16 hours. To generate total cell lysates, equal amounts
of cells were washed with PBS and directly lysed in SDS sample buffer
containing β-mercaptoethanol. For detergent-insoluble fractions, cells
were lysed in TNES buffer (50 mM Tris-HCl, pH 7.5, 1% NP-40,
2 mM EDTA, 100 mM NaCl), with freshly added protease inhibitor
cocktail (Serva, Heidelberg, Germany). The supernatants contain the
soluble fractions. NP-40 detergent-insoluble pellets were resuspended
in TNES buffer and sonificated for 10 seconds at 50 Won ice using a
homogenizer (SONOPLUS; Bandlin Electronics, Berlin, Germany).
Protein concentrations were colorimetrically determined using bi-
cinchoninic acid (BCA Protein Assay; Pierce, Rockford, IL). Proteins
were separated on 10% or 12% SDS–polyacrylamide gels and trans-
ferred onto nitrocellulose membranes (Schleicher & Schuell, Dassel,
Germany). Membranes were blocked with 5% nonfat dry milk (Roth,
Karlsruhe, Germany), probed with antibodies and developed using the
enhanced chemiluminescence method.
Electromobility Shift Analysis
Electromobility shift analysis (EMSA) was performed using oligo-
nucleotides for NF-κB end labeled with IRDye according to the man-
ufacturer’s instructions (Metabion, Planegg-Martinsried, Germany).
Briefly, cells (5 × 106) were treated with 10 nM bortezomib and/or
70 μMverapamil for 8 hours, and nuclear extracts were prepared as pre-
viously described [9]. Ten microliters of probe mix (1 μg poly-dIdC,
0.25% Tween 20, 0.1% NP-40, 20 μg BSA, 1 × lipage buffer [0.1 M
Tris-HCl, pH 7.5, 0.5 MNaCl, 10 mM EDTA, pH 7.5, 50% glycerol,
before usage add 0.5 mM DTT], 0.1 pM oligo-IRDye-700) and
Orange G loading buffer (20 mg Orange G, 15% Ficoll) were added
to 10 μg of nuclear extracts. The reaction mixtures were incubated by
gently shaking at room temperature for 30 minutes in the dark. After a
prerun for 30 to 60 minutes at 150 V, samples were loaded on a 4%
nondenaturing polyacrylamide gel and run for 2.5 hours at 150 V. Gels
were analyzed using an Odyssey infrared imaging system (LI-COR Bio-
sciences, Bad Homburg, Germany).
Reverse Transcription–Polymerase Chain Reaction Analyses
Cells (2 × 106) were treated with 10 nM bortezomib and/or 70 μM
verapamil for up to 12 hours. Total RNA was isolated using the Mini
RNAeasy Kit (Qiagen, Hilden, Germany), including digestion with
RNase-free DNAse. Complementary DNA (cDNA) synthesis from
1 μg total RNA was performed using the SuperScript II Reverse Tran-
scriptase (Invitrogen, Karlsruhe, Germany) and amplified with Taq
polymerase (NEB, Frankfurt/Main, Germany) using specific primers
for XBP-1. Polymerase chain reaction (PCR) products were separated
by electrophoresis on 2% agarose gel and visualized by ethidium bro-
mide staining. Levels of glyceraldehyde 3-phosphate dehydrogenase
messenger RNA (mRNA) were used for adjustment of the mRNA con-
centrations. For quantitative real-time PCR analysis, the cDNA and ap-
propriate primers were mixed with 2× ABsolute qRT-PCR SYBR green
ROX reagent (Abgene, Hamburg, Germany). The following primers
were used: CHOP forward, 5′ GAAACGGAAACAGAGTGGTCA-
TTCCCC 3′, reverse, 5′ GTGGGATTGAGGGTCACATCATTGG-
CA 3′; mdr1 forward, 5′ GCTCAGACAGGATGTGAGTTGG 3′,
reverse, 5′ TAGCCCCTTTAACTTGAGCAGC 3′. Primer sequences
for IκBα, BiP, Bcl-2, Bax, β5-subunit, and β-actinwere retrieved from an
online database (Primer Bank, Harvard.edu). Real-time PCR was per-
formed in triplicates in an Applied Biosystems 7300 real-time PCR sys-
tem (Applied Biosystems, Darmstadt, Germany).
Enzyme-Linked Immunosorbent Assay
Sandwich ELISA was performed to quantify total IgG in the super-
natant of JK-6L cells (2 × 106) treated with 10 nM bortezomib and/
or 70 μM verapamil for 16 hours. Diluted supernatants and standard
sera ( Jackson Immunoresearch Laboratories, Inc) were incubated on
IgG-coated Maxisorp microplates (Thermo Fisher Scientific, Roskilde,
Denmark), and bound IgG was detected with horseradish peroxidase–
conjugated IgG. O-phenylenediamine dihydrochloride (Sigma-Aldrich)
was used as substrate. Optical density was measured at 495 nm in a
SpectraMax 190ELISA reader (MolecularDevices, Ismaning,Germany).
Transmission Electron Microscopy
Cells (2 × 106) treated with bortezomib and/or verapamil were fixed
in 2.5% glutaraldehyde in 0.2 M phosphate buffer (pH 7.4), postfixed
in 2%buffered osmium tetroxide, dehydrated in graded alcohol concen-
trations, and embedded in epoxy resin according to standard protocols.
For orientation, 1-μm semithin sections were stained with toluidine
blue. Ultrathin sections were stained with uranyl acetate and lead citrate
and examined using a transmission electron microscope (EM 906E;
Carl Zeiss NTS GmbH, Oberkochen, Germany).
Results
Verapamil Synergistically Decreased Viability of Bortezomib-
Treated Myeloma Cell Lines
We first assessed the effect of bortezomib and verapamil alone and in
combination on the viability of myeloma cell lines. The concentrations
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necessary for efficient depletion of myeloma cells were determined by
performing titration curves. On the basis of this titration, we used 70μM
verapamil and a minimum of 10 nM bortezomib in the following
studies (Figure 1A). Importantly, the combination of bortezomib
and verapamil markedly declined the viability of the JK-6L, RPMI
8226, and ARH-77 cell lines after 16 hours of culture (Figure 1B).
Bortezomib reduced the viability of all used myeloma cell lines, whereas
verapamil alone exhibited just a slight cytotoxic effect on JK-6L cells
but none on RPMI 8226 and ARH-77 cells. Compared with the other
cell lines, JK-6L cells were more sensitive toward bortezomib and verapa-
mil treatment, most likely because of their higher immunoglobulin chain
expression as analyzed by intracellular flow cytometry and secretion
assays (data not shown), consistent with previous results [9,10]. Most
of the following analyses were performed with the JK-6L cell line because
it is especially sensitive against bortezomib and verapamil.
Next we analyzed the induction of cell death on bortezomib and ve-
rapamil treatment. As displayed in Figure 1C , the combination of bor-
tezomib and verapamil markedly diminished the percentage of annexin
V/propidium iodide double-negative viablemyeloma cells while increas-
ing apoptosis and necrosis, especially in JK-6L cells. At earlier time
Figure 1. Bortezomib together with verapamil synergistically reduces viability in humanmyeloma cell lines. (A) JK-6L cells were treated with
increasing concentrations of verapamil as indicated (solid line) and in combination with 10 nM bortezomib (discontinuous line) for 16 hours.
Cells were incubated with the vital dye AlamarBlue. The absorbance (OD) was measured using a spectrophotometer. Mean values and SD
were calculated from triplicates. (B)Myeloma cell lineswere treatedwith 10 nMbortezomib and 70 μMverapamil or the combination of both
inhibitors for 16 hours. Cells were incubatedwith the vital dye AlamarBlue. The absorbance (OD) wasmeasured using a spectrophotometer.
Mean values and SDwere calculated from hexaplicates. (C) Myeloma cell lines were treated with 10 nM bortezomib and 70 μM verapamil or
the combination of both inhibitors for 16 hours. Diagrams show the percentages of viable (annexin V–FITCnegative/propidium iodidenegative),
apoptotic (annexin V–FITCpositive/propidium iodidenegative), and necrotic/late apoptotic (annexin V–FITCpositive/propidium iodidepositive) cells,
analyzed by flow cytometry. Mean values and SD were calculated from triplicates. (D) JK-6L cells were treated with 10 nM bortezomib
and 70 μM verapamil or the combination of both inhibitors for 16 hours. Caspase 3/7 activity was determined using the luminescence-based
Caspase-Glo assay. Mean values and SD were calculated from quadruplicates. (E) JK-6L cells were treated with the inhibitors in the pres-
ence or absence of the caspase inhibitor zVAD-FMK. The diagrams show the percentages of viable cells (annexin V–FITCnegative/propidium
iodidenegative) analyzed by flow cytometry. Mean values and SD were calculated from triplicates. All these data represent one of three inde-
pendently done experiments. Student’s t-test for unpaired heteroscedastic samples was used for statistical analysis. #P < .05, *P < .01,
**P < .001, ***P < .0001. AxV indicates annexin V–FITC; Bz, bortezomib; Co, control (PBS-treated); PI, propidium iodide; Vp, verapamil.
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points, we could detect almost exclusively apoptotic cells and not ne-
crotic ones (data not shown). Hence, combination of bortezomib and
verapamil may induce predominantly apoptotic cell death, and the an-
nexin V/propidium iodide–positive cells represent late apoptotic rather
than primary necrotic cells. In contrast to verapamil alone, bortezomib,
and even more when combined with verapamil, strongly induced acti-
vation of caspase 3/7 (Figure 1D). To evaluate the functional importance
of bortezomib- and verapamil-induced caspase activation for apoptosis,
we examined the influence of the pan-caspase inhibitor zVAD-FMK.
Figure 1E shows that zVAD-FMK significantly interfered with cell
death triggered either by the combination of both inhibitors or by bor-
tezomib alone. Thus, bortezomib-induced apoptotic cell death was sig-
nificantly enhanced in the presence of verapamil.
Proteasomal Activity Was Not Altered by Verapamil
To elucidate the mechanisms by which verapamil enhances the anti-
myeloma effect of bortezomib, we first analyzed the proteasomal activity
of the JK-6L cells during the treatment. The chymotrypsin-like activity
Figure 2. JK-6L cells show decreased NF-κB activity on bortezomib and verapamil combination. (A) Proteasomal activity of JK-6L cells treated
with 10 nM bortezomib and/or 70 μM verapamil for 8 hours. The chymotrypsin-like activity was determined using the luminescence-based
Proteasome-Glo assay. Mean values and SD were calculated from quadruplicates. Data represent one of three independently experiments.
(B) Western blot analysis of total cell lysates from JK-6L cells treated with 10 nM bortezomib and/or 70 μM verapamil for 8 hours. Anti-actin
antibody staining served as control for an equal loading. One representative immunoblot of two independent experiments is shown. (C)
EMSA was performed with nuclear extracts prepared from JK-6L cells treated with 10 nM bortezomib and/or 70 μM verapamil for 8 hours.
NF-κB DNA-binding activity was analyzed using IRDye end-labeled probes containing specific binding sites. As control, gel was loaded with
free-labeled probes without nuclear extract. The intensity of NF-κB DNA binding activity is displayed as arbitrary light units. Data represent
one of two independently performed experiments. (D) Myeloma cell lines were treated with 10 nM bortezomib and 70 μM verapamil or the
combination of both inhibitors in the absence or presence of 20 μMNF-κB inhibitor PS-1145 for 16 hours. Cells were incubated with the vital
dye AlamarBlue. The absorbance (OD) was measured using a spectrophotometer. Only relevant significance values were depicted. (E) Quan-
titative real-time PCRanalysis of total RNA isolated from JK-6L treatedwith 10 nMbortezomib and/or 70 μMfor 8 hours. The diagrams show the
relative IκBαmRNA levels of bortezomib-treated JK-6L cells normalized to β-actin mRNA levels, which served as internal control. cDNA from
PBS-treated cells served as reference control. The comparativeCt (DDCT)method for relative quantification of gene expressionwasused.Mean
values andSDwere calculated from triplicates.Data represent one of two independently done experiments. Student’s t-test for unpaired hetero-
scedastic samples was used for statistical analysis. #P< .05, *P< .01, **P< .001, ***P< .0001. Bz indicates bortezomib; Co, control (PBS-
treated); Vp, verapamil.
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of the 20S proteasome was completely blocked by bortezomib, whereas
it was not affected by verapamil alone. Also, the combination of bor-
tezomib and verapamil did not further decrease the proteasomal ac-
tivity (Figure 2A). The concentration of the subunit β5 accounting for
the chymotrypsin-like activity of the constitutive 26S proteasome mod-
erately decreased after incubating with bortezomib (Figure 2B). Beside
that, the immunoproteasomal subunit LMP7 that corresponds to β5 was
not altered after treatment with the inhibitors (Figure 2B). Verapamil
itself exerts no major effect on proteasomal activity.
Combination of Verapamil and Bortezomib Resulted in
NF-κB Inhibition
The transcription factor NF-κBwas shown to be constitutively active
in myeloma cells and to be essential for their survival [19]. To quantify
the NF-κB DNA-binding activity, nuclear extracts from JK-6L cells
treated with bortezomib and/or verapamil were analyzed by EMSA
(Figure 2C ). Bortezomib together with verapamil markedly decreased
the NF-κB DNA-binding activity in JK-6L myeloma cells, whereas
bortezomib or verapamil alone rather somewhat increased the constitu-
tive NF-κB activity after 8 hours (Figure 2C). Incubation of JK-6L cells
with an IKK inhibitor combined with verapamil resulted in a stronger
reduction of the cell viability than in cells treated with verapamil only,
suggesting that this specificNF-κBblockademay account for verapamil-
induced synergistic cytotoxicity (Figure 2D).
We also measured the IκBαmRNA expression, which is strongly in-
duced byNF-κB activation and therefore reflects transcriptional activity
of NF-κB [20]. Consistent with NF-κBDNA-binding activity, the rela-
tive IκBα mRNA concentrations dropped on the combination treat-
ment (Figure 2D), indicating that NF-κB transcriptional activity was
decreased. Thus, the blockade of the survival factor NF-κB on combi-
nation of bortezomib with verapamil might be crucial for enhancement
of cell death.
Verapamil Enhanced Bortezomib-Triggered UPR Signals
To investigate whether verapamil together with bortezomib induced
terminal UPR signals, we analyzed prominent UPR components in ly-
sates of JK-6L cells. Enhanced chaperone production is a hallmark of
UPR activation. Induction of the ER resident chaperone μ-heavy chain
binding protein (BiP) is observed in bortezomib-treated cells. However,
there was no additional increase of BiP expression in the presence of
verapamil (Figure 3A). GRP94 was slightly upregulated on combination
therapy compared with monotherapy. Hsp70, however, was strongly in-
duced by bortezomib and its expression was further augmented in com-
bination with verapamil (Figure 3A).
The transmembrane factor ATF6 induces transcription of several
genes including chaperones, XBP-1, and CEB/P homologous protein
(CHOP) in response to ER stress [21]. After bortezomib and/or verapa-
mil treatment, ATF6 was activated as shown by reduced expression of its
inactive 90-kDa precursor form (Figure 3A). We also observed a slight
induction of XBP-1mainly triggered by bortezomib. The splicedXBP-1
protein was present in bortezomib-treated cells and synergistically in-
creased on bortezomib and verapamil application (Figure 3A). Splicing
of XBP-1 mRNA is induced by IRE1α to generate a transcript encod-
ing an XBP-1 protein. The splicing results in the translation of a larger
XBP-1 protein [22]. In contrast to protein expression, analysis of
XBP-1 mRNA revealed a strong activation of XBP-1 evidenced by
the generation of the two splicing products on treatment with bortezo-
mib plus verapamil (Figure 3B). The proapoptotic factor CHOP is
markedly induced in cells incubated with bortezomib plus verapamil
(Figure 3A), suggesting that verapamil strengthened the effect of the pro-
teasome inhibitor.
As shown in Figure 3A, IRE1 expression itself was upregulated after
bortezomib/verapamil treatment compared with monotherapy, indicat-
ing that verapamil enhanced the effect of bortezomib. On ER stress,
IRE1 stimulates p38, causing activation of JNK. The p38 mitogen-
activated protein kinase was highly activated evidenced by a strong
expression of phosphorylated p38 (Figure 3A). Bortezomib/verapamil
treatment eventually induced active JNK2 proposed to promote cell
death (Figure 3A). These results imply that the ATF6/ IRE1 signaling
plays an important role in the bortezomib/verapamil–mediated ER
stress response.
In cells with irrecoverable levels of ER stress, the IRE1 pathway can
promote apoptosis by interaction with Bcl-2 family members [23]. The
proapoptotic factor Bax is strongly expressed in double-treated JK-6L
cells, whereas Bcl-2 was not markedly altered, if at all there was a slight
increase on treatment with either bortezomib or verapamil alone (Fig-
ure 3A). The BH3-only protein Bim, a crucial effector of the IRE1-JNK
pathway [24], was also induced by bortezomib together with verapamil.
Induction of the key UPR molecules BiP, CHOP, Bim, and Bax could
be confirmed in the myeloma cell lines ARH-77 and RPMI 8226
(Figure 3A).
PERK phosphorylates and inactivates the eukaryotic elongation
factor eIF2α reducing the protein load through translational attenua-
tion. Active p-eIF2α increases expression of the transcription factor
ATF4, which induces UPR target genes [21]. Western blot analyses re-
vealed increasing PERK phosphorylation in bortezomib-, verapamil-,
and bortezomib/verapamil–treated cells (Figure 3A). We also detected
highly activated eIF2α in samples incubated with bortezomib plus ve-
rapamil (Figure 3A). At early time points, ATF4 was only induced in
cells treated with verapamil after 16 hours; however, ATF4 expression
was augmented on all different treatment regimens (Figure 3A). These
data suggest a possible role for the PERK pathway in bortezomib/
verapamil–mediated cellular effects, most notably for the calcium chan-
nel blocker verapamil.
To confirm induction of the UPR target genes on the transcriptional
level, we performed quantitative reverse transcription–PCR. Here, we
focused on UPR genes that are mainly involved in mediating survival
and apoptosis. In contrast to BiP protein synthesis, we observed a stron-
ger increase of BiP mRNA in cells treated with the drug combination
(Figure 3C ). Consistent with protein expression, analysis of CHOP
mRNA revealed a more than 40-fold higher expression in response
to bortezomib plus verapamil compared with untreated cells (Fig-
ure 3C ). Bcl-2 mRNA was slightly downregulated, whereas Bax was
increased by adding bortezomib plus verapamil (Figure 3C ). Hence,
bortezomib-triggered transcriptional activation of the terminal UPR
was enhanced by combination with verapamil.
Bortezomib Plus Verapamil Activated Caspases
JNK activation can promote apoptosis in cells with overwhelm-
ing stress through activation of caspases [25]. Hence, we investigated
whether the inhibitors bortezomib and verapamil lead to caspase acti-
vation. Figure 3A demonstrates that after treatment with the drug com-
bination, procaspase 9 virtually disappeared, indicating caspase 9
activation; verapamil alone had no effect on caspase 9 activation. Activa-
tion of the procaspase 9 was also observed in the ARH-77 and RPMI
8226 myeloma cell lines (Figure 3A). Likewise, a luminescence-based
assay revealed that caspase 3/7 activation is more pronounced on the
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combination of bortezomib and verapamil than after monotherapy (Fig-
ure 1D). Further, bortezomib induced PARP activation as evidenced by
detection of the cleavage product. The cleavage bandwas induced by bor-
tezomib and even stronger in combination with verapamil (Figure 3A).
Together, the bortezomib plus verapamil treatment resulted in caspase
activation followed by PARP cleavage, finally leading to cell death.
Accumulation of Polyubiquitinylated Proteins in Cells
Incubated with Verapamil/Bortezomib
To be degraded by the 26S proteasome, misfolded proteins have
to get ubiquitinylated. On proteasome inhibition, these proteins can
accumulate as insoluble intracellular aggregates up to cytotoxic levels
[26]. As depicted in Figure 4A, both bortezomib and verapamil induced
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accumulation of ubiquitinylated proteins after 16 hours in the soluble
and insoluble fractions; also, after 8 hours, we observed ubiquitinyla-
tion of soluble but not of insoluble proteins (Figure W1). There was
no marked further increase of ubiquitinylated proteins in the soluble
fractions after combination treatment, also reflected by the pool of
free ubiquitin. However, the amount of ubiquitinylated proteins in
detergent-insoluble fractions was much higher in the presence of
bortezomib plus verapamil, indicating an increased formation of intra-
cellular protein aggregates.
Further, verapamil as well as bortezomib leads to the reduction of
IgG in the supernatant of JK-6L cells as observed by ELISA andWestern
blot analysis. Intracellular IgG was upregulated by adding verapamil
(Figure 4B). Hence, bortezomib reduced IgG secretion presumably by
UPR-mediated blockade of protein synthesis; whereas verapamil may
interfere with IgG secretion (Figure 4C ). We exclude the induction of
apoptosis because IgG expression was also reduced at earlier time points
(4 hours; Figure 4B).
Vast Dilation of the ER and Induction of an Autophagy-like
Process on Combination Therapy
To assess subcellular alterations induced by bortezomib and verapa-
mil, we performed transmission electron microscopy of JK-6L cells.
Bortezomib treatment resulted in ER dilation after 8 hours, most likely
induced through accumulation of misfolded proteins, which even fur-
ther increased after 16 hours (Figure 5A). Importantly, we observed
vesicle-like intracellular structures after verapamil administration,
suggesting that calcium channel blockade induced autophagy in the
myeloma cells (Figure 5A). Visible signs of ER stress evidenced by ER
Figure 4. JK-6L cells show enhanced protein accumulation in the presence of bortezomib and verapamil. (A) Western blot analysis of
detergent-soluble and detergent-insoluble fractions of JK-6L cells treated with 10 nM bortezomib and/or 70 μM verapamil for 16 hours. Im-
munoblot analysiswas doneusing an anti-ubiquitin antibody. To detect free ubiquitin, a denser gelwas used.One representative immunoblot
of two independent experiments is shown. (B)Western blot analysis of total cell lysates from JK-6L cells treatedwith 10 nMbortezomib and/
or 70 μMverapamil for 16 hours. Immunoblot analysiswas done using HRP-conjugated anti-IgG antibody. One representative immunoblot of
two independent experiments is shown. (C) IgG concentration in the supernatant of JK-6L cells treatedwith 10 nMbortezomib and/or 70 μM
verapamil for 16 hourswasdeterminedbyELISA. The absorbance (OD)wasmeasuredusing a spectrophotometer.Mean values andSDwere
calculated fromhexaplicates. Data represent one of two independently done experiments. Student’s t-test for unpaired heteroscedastic sam-
ples was used for statistical analysis. #P< .05, *P< .01, **P< .001, ***P< .0001. Bz indicates bortezomib; Co, control (PBS-treated); HC,
heavy chain; Vp, verapamil.
Figure 3. Verapamil enhances the bortezomib-inducedUPR activation in JK-6L cells. (A)Western blot analysis of total cell lysates from JK-6L,
ARH-77, and RPMI 8226 cells treated with 10 nM bortezomib and/or 70 μM verapamil for 16 hours. Anti-actin antibody staining served as
control for equal loading.One representative immunoblot of three independent experiments is shown. (B) Reverse transcription–PCRanalysis
of total RNA isolated from JK-6L cells treated with 10 nM bortezomib and/or 70 μM verapamil. Reverse transcription–PCR was done using a
primer set that detects the unspliced (442 bp) and spliced (416 bp) form of XBP-1 mRNA. Data represent one of two independently done
experiments. (C) Quantitative real-time PCR analysis of total RNA isolated from JK-6L cells treated with 10 nM bortezomib and/or 70 μM
verapamil for 12 hours. The diagrams show relative mRNA levels of treated JK-6L cells normalized to β-actin mRNA levels, which served
as internal control. cDNA from PBS-treated cells served as reference control. The comparative Ct (DDCT) method for relative quantification
of gene expression was used. Mean values and SD were calculated from triplicates. Data represent one of two independently done experi-
ments. Student’s t-test for unpaired heteroscedastic samples was used for statistical analysis. #P< .05, *P< .01, **P< .001, ***P< .0001.
Bz indicates bortezomib; Co, control (PBS-treated); Vp, verapamil; XBP-1u, unspliced; XBP-1s, spliced.
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expansion together with the appearance of protein deposits were de-
tected 8 hours after combined treatment with bortezomib plus verapa-
mil (Figure 5A). Aside increased autophagosomes, a vast swelling of
the mitochondria was also observed after incubation with verapamil
(Figure 5A). Consistent with the viability and UPR data, we observed
a massive ER expansion along with vacuolization accompanied by
morphologic features of apoptosis after 16 hours of incubation with this
drug combination (Figure 5A).
To corroborate the morphologic evidence of verapamil-induced auto-
phagy in myeloma cells, we analyzed the autophagosome formation
Figure 5. Verapamil induces an autophagy-like process in JK-6L cells. (A) Transmission electron microscopy analysis of ultrathin sections
of JK-6L cells treated with 10 nM bortezomib and/or 70 μM verapamil for 16 hours. Bortezomib-treated cells show dilated ER (arrows).
Verapamil-treated cells contain autophagosomes (arrows) and expanded mitochondria (one arrow). The magnification of verapamil-treated
cells displays in greater detail the expanded and stressed mitochondria (upper right panel). The lower right panel shows a magnification of
cells treated with bortezomib and verapamil, clearly displaying autophagosomes engulfing cellular constituents. The scale bar shows a
longitude of 2.0 μm. (B) Western blot analysis of total cell lysates from JK-6L cells treated with 10 nM bortezomib and/or 70 μM verapamil
for 16 hours. Cell lysates were separated by SDS-PAGE on a 12% polyacrylamide gel, and immunoblot analysis was done using an anti-LC3
antibody. Antiactin antibody staining served as control for equal loading. (C) Mitochondrial transmembrane potential of JK-6L cells treated
with 40 nM bortezomib and/or 70 μM verapamil for 10 hours. Cells were double stained with DiOC6 dye and propidium iodide (to exclude
necrotic cells) and analyzed by flow cytometry. The alteration of the mitochondrial transmembrane potential of propidium iodidenegative/
DiOC6
positive cells is displayed in the diagram. The control was set as 1.0.Mean values and SDwere calculated from triplicates. Data represent
one of two independently performed experiments. (D) ROS production of JK-6L cells treatedwith 40 nMbortezomib and/or 70 μMverapamil
for 2 hours and incubated in the presence of with DCFH. The DCF fluorescence intensity was determined by flow cytometric analysis. H2O2
served as positive control. To eliminate ROSproduction, cellswere treatedwith NAC. Themean fluorescence intensities (MFIs) are displayed
in the diagram. Mean values and SD were calculated from triplicates. Data represent one of three independently performed experiments.
Student’s t-test for unpaired heteroscedastic samples was used for statistical analysis. #P < .05, *P < .01, **P < .001, ***P < .0001.
Bz indicates bortezomib; Co, control (PBS-treated); Vp, verapamil.
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using the microtubule-associated protein 1 light chain 3 (LC3; Fig-
ure 5B). LC3 is processed posttranslationally into LC3-I, then converted
to LC3-II that is specifically associated with autophagosomemembranes
[27]. LC3-II concentrations, correlating with autophagosome numbers,
were increased by verapamil and even further in combination with bor-
tezomib, suggesting enhanced autophagy (Figure 5B).
Changes in mitochondrial structure may correlate with dysfunction
of the mitochondria. We therefore determined the mitochondrial mem-
brane potential: The percentage of DiOC6-positive cells decreased in
the presence of the drugs (Figure 5C), indicating that both bortezomib
and verapamil induced disruption of the mitochondrial membrane
potential. However, the loss of the mitochondrial potential was more
pronounced in bortezomib-treated than in verapamil-treated cells.
Importantly, in response to verapamil treatment, we observed a vast
and significant accumulation of ROS, which was reduced by the anti-
oxidant NAC (Figure 5D), possibly linking increased ROS production
to depolarization of the inner mitochondrial membrane.
Verapamil Decreased P-gp Expression in Myeloma Cells
As verapamil diminished expression of P-gp in resistant leukemic cells
[16], we determined the effect of verapamil and bortezomib on P-gp
expression on JK-6L cells. Flow cytometric analyses revealed decreased
expression of P-gp on the JK-6L cells when treated with verapamil (Fig-
ure 6A). There was a slight effect of bortezomib alone but no synergistic
effect together with verapamil on P-gp expression (Figure 6A). MDR1
mRNA levels significantly declined on verapamil monotherapy (Fig-
ure 6B). Hence, we conclude that P-gp expression on JK-6L was pre-
dominantly inhibited by verapamil.
Discussion
Bortezomib exhibits antitumor activities by inducing cell death, but
long-term administration often leads to secondary resistance of mye-
loma cells [19]. To overcome cellular resistance and to enhance bor-
tezomib’s selectivity for myeloma cells, we searched for agents that
synergistically increase the antitumor effect of bortezomib. The calcium
channel blocker verapamil represented a promising candidate because
it was shown to reduce MDR1-mediated drug resistance in leukemia
cells [16]. Our present study revealed that verapamil enhanced the anti-
myeloma effect of bortezomib leading to increased cell death in myeloma
cells. It remains to be investigated if such high plasma levels of verapamil
required to exert synergistic effects can be achieved in vivo without seri-
ous toxicity. ROS production and autophagy-like processes induced by
verapamil might contribute to elevation of proapoptotic stress signals,
strongly activating the terminal UPR in bortezomib-treated cells.
One important mechanism of bortezomib is the UPR induction that
can trigger tumor cell death due to prolonged ER stress. This stress re-
sponse can be induced through accumulation of misfolded immuno-
globulin chains/DRiPs in the ER caused by proteasome inhibition
[9,28]. Our results demonstrated that verapamil is able to enhance pro-
apoptotic stress signals triggered by bortezomib. Depending on the
UPR branch, the calcium channel inhibitor verapamil alone had only
slight effects on UPR induction compared with bortezomib or the com-
bination therapy. Also, verapamil displayed no direct effect on the 26S
proteasome activity, suggesting that the ER-associated degradation
is not blocked by verapamil. In contrast to our findings, Fekete et al.
[29] observed an inhibition of proteasomal activity by verapamil in
human epitheloid carcinoma cells; possibly, this discrepancy is due to
the different reactions of individual cell species.
The expression of the chaperone BiP did not markedly change be-
tween treated cells, likely because of the relatively high basal levels of this
protein often found in myeloma cells [10]; the BiP mRNA, however,
was strongly induced. Likewise, an increase in cellular BiP mRNA does
not necessarily lead to increased synthesis of BiP, and protein levels can
remain constant [30]. A need for more folding capacity was also
evidenced by an induction of the ER resident chaperone GRP94 after
bortezomib/verapamil treatment. Hsp70, the cytosolic homolog of
BiP, was markedly increased in the presence of bortezomib and ve-
rapamil, indicating activation of a mitochondrial-like stress [31]. One
function of chaperones is to protect cells against ER stress–induced
apoptosis, but in case of prolonged or overwhelming stress signals, the
UPR ends in apoptosis. In our approach, the IRE1-mediated pathway
was profoundly activated. By recruiting TRAF2, IRE1 leads to increased
levels of phosphorylated p38 mitogen-activated protein kinase causing
JNK activation [32] that can foster apoptosis through activation of
caspases under severe stress induction [25]. On treatment with the com-
bination of bortezomib and verapamil, p38 was strongly activated fol-
lowed by JNK activation, suggesting that the IRE1-p38-JNK signaling
plays an important role in bortezomib/verapamil–mediated cell death.
Also, CHOP expression is enhanced by verapamil when combined
with bortezomib. CHOP, which is associated with the terminal UPR
and apoptosis, was shown to downregulate Bcl-2 [33]. A recent publi-
cation demonstrated that CHOP itself is not essential for physiologic
cell death in mouse B and plasma cells [34]. Expression of the proapop-
totic Bax increased in response to combination treatment, whereas there
Figure 6. Verapamil impairs P-gp function in JK-6L cells. (A) Quanti-
tative real-time PCR analysis of total RNA isolated from JK-6L cells
treatedwith 10 nMbortezomib and/or 70 μMverapamil for 12 hours.
The diagram shows relative MDR1 mRNA levels of treated JK-6L
cells normalized to β-actin mRNA levels, which served as internal
control. cDNA from PBS-treated cells served as reference control.
The comparative Ct (DDCT) method for relative quantification of
gene expression was used. (B) Surface expression of MDR1 on
JK-6L cells treated with 10 nM bortezomib and/or 70 μM verapamil
for 16 hours was analyzed by flow cytometry. Mean values and SD
were calculated from triplicates. All these data represent one of two
independently performed experiments. Student’s t-test for unpaired
heteroscedastic samples was used for statistical analysis. #P< .05,
*P < .01, **P < .001, *** P < .0001. Bz indicates bortezomib; Co,
control (PBS-treated); Vp, verapamil.
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was no significant difference in Bcl-2 levels. Importantly, Bax and Bcl-2
can also activate IRE1 [23], thereby providing a connection between
UPR and apoptosis pathways. The role of CHOP in human myeloma
cells is not yet resolved.
The role of the PERK pathway in cell death regulation remains to be
elucidated. Its activation initiates inhibition of translation via phosphor-
ylation of eIF2α to protect the cell from protein overload. The PERK
pathway was highly activated on treatment with verapamil and the com-
bination of bortezomib and verapamil as shown by up-regulation of
p-eIF2α, suggesting attenuation of mRNA translation. In addition,
PERK-mediated eIF2α phosphorylation contributes to transcriptional
activation of ATF4, which has been shown to stimulate expression of
autophagy genes [35] and to induce CHOP [21]. Also, long-lasting sup-
pression of protein synthesis is not compatible with cell survival and can
induce autophagy known to require PERK and eIF2α phosphorylation.
Using transmission electronmicroscopy, we detected a vast expansion of
mitochondria and formation of cytosolic vesicles on verapamil exposure.
These observations suggest that verapamil induces autophagy in the
myeloma cells. Autophagy, an intracellular degradation system of cyto-
plasmic contents and organelles, is required for normal turnover of
cellular components during starvation in eukaryotic cells. The autopha-
gosomes, with two or more membranes enclosed vesicles, engulf various
cellular constituents that fuse with lysosomes for degradation and recy-
cling [36]. Autophagy is also characterized by dilation of mitochondria
that we observed in treated JK-6L cells. Besides promoting cell survival,
autophagy can trigger caspase-independent cell death [36]. Likewise,
we observed no caspase activation by verapamil. A very recent study
by Williams et al. [37] revealed that verapamil stimulates autophagy
by reducing the calcium influx. Notably, verapamil diminished the in-
tracellular calcium level also in the myeloma cell lines (Figure W2).
Changes in calcium homeostasis may foster ER stress triggering auto-
phagy by the ER-activated autophagy pathway. The latter could be me-
diated by limited UPR signals involving PERK and/or IRE1 as well as
UPR-independent mechanism such as calcium leakage ( JNK-AKT/
mTOR signaling) [38]. Here, we demonstrate that verapamil enhanced
IRE1- and PERK-mediated pathways, indicating that verapamil further
activates the UPR and might trigger an autophagic, caspase-independent
cell death. In the presence of the autophagy inhibitor 3-methyladenine,
we observed a higher viability in verapamil-treated cells compared
with cells cultured with verapamil alone (Figure W3), suggesting that
verapamil-induced autophagy might contribute to cytotoxicity. Verapa-
mil treatment also increased ROS production, leading to oxidative stress
that was also shown to activate autophagy andmitochondrial dysfunction
[39]. Mitochondrial ROS can further increase calcium release from the
ER, thereby causing protein misfolding. ROS production and protein
misfolding together activate calcium-dependent kinases such as
JNK eventually leading to cell death [40]. Thus, we showed that verapa-
mil supports bortezomib’s ability to promote proapoptotic UPR signals
such as CHOP induction and JNK activation. Bortezomib itself leads
usually to a slight induction of NF-κB, presumably due to ER stress
and consecutive UPR activation, which is not completely blocked by
bortezomib-mediated inhibition of IκB degradation, as recently de-
scribed by Hideshima et al. [41]. Remarkably, combination treatment
with bortezomib and verapamil markedly inhibited the transcription fac-
tor NF-κB, a fact which might critically contribute to cell death induc-
tion in JK-6L cells. Moreover, autophagy-induced protein degradation
could further decrease NF-κB activity [42].
Interference with MDR represents a further potential mechanism
to increase cytotoxicity by the combination of the two drugs. Verapamil
functions as an inhibitor of drug efflux pump proteins such as the P-gp
[15]. Many tumor cell lines overexpress drug efflux pumps, limiting the
effectiveness of cytotoxic drugs. A recent study showed that efflux pump
inhibitors enhanced the effect of bortezomib on drug-resistant Ewing
tumors [43]. Using P-gp–positive and P-gp–negative cells, Rumpold
et al. [44] provided evidence that bortezomib acts as a MDR1 substrate.
We observed lower P-gp expression on JK-6L cells accompanied by im-
paired efflux of daunorubicin in cells treated with bortezomib/verapamil
(data not shown), speculating that inhibition of P-gp might result in
a reduced bortezomib efflux, leading to increasing amounts of intra-
cellular bortezomib concentrations augmenting cell stress.
Approximately 60% of nonresistant JK-6L myeloma cells express
P-gp on their surface. As expected, long-term culturing in the presence
of bortezomib rendered these cells resistant to bortezomib, resulting in
an increased P-gp expression (data not shown). These resistant JK-6L
cells could be partially sensitized against bortezomib by verapamil
(Figure W4). However, we assume that the increased sensitivity mainly
results from UPR/stress–induced apoptosis and simultaneous inhibi-
tion of the antiapoptotic factor NF-κB, whereas the subtle MDR-
mediated effects may play only a minor role. Further investigations
are required to elucidate the exact mechanisms how verapamil triggers
these signals.
In summary, our data provide a biochemical base for a new potential
combination therapy of bortezomib together with verapamil, which
should markedly enhance the killing of myeloma cells. Moreover, the
efficiency of bortezomib treatment can be enhanced by the combination
with verapamil. In addition, this drug combination may allow decreas-
ing the bortezomib dose thereby reducing adverse effects. Animal experi-
ments exploring the use of this combination treatment in myeloma
models are underway.
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Figure W1. Combination treatment of bortezomib and verapamil for
8 hours resulted in the accumulation of ubiquitinylated proteins in
soluble fractions. Western blot analysis of detergent-soluble and
detergent-insoluble fractions of JK-6L cells treated with 10 nM bor-
tezomib and/or 70μMverapamil for 8 hours. Immunoblot analysiswas
done using an antiubiquitin antibody. One representative immuno-
blot of two independent experiments is shown. Bz indicates borte-
zomib; Co, control (PBS-treated); Vp, verapamil.
Figure W2. The intracellular calcium level was diminished by verapa-
mil inmyeloma cell lines. (A–C)Myeloma cells (1× 106) were treated
with 10 nM bortezomib and/or 70 μM verapamil for 2 hours. To eval-
uate the cellular Ca2+ flux, cellswere harvested by centrifugation and
resuspended with 0.8 ml of Fluo-8 NW dye-loading solution from
the Screen Quest Fluo-8 NW Calcium Assay Kit (ATT Bioquest Inc,
Sunnyvale, CA). The cell suspension was plated 100 μl per well in a
96-well black well plate (Nunc; Thermo Fisher Scientific) precoated
with poly-L-lysine (Sigma). The plates were incubated at 37°C for
30minutes and then placed at room temperature for another 30min-
utes. Fluorescence at Ex = 485 nm/Em = 535 nm was measured
by a bioassay reader (HTS 7000; PerkinElmer, Waltham, MA) and
depicted as relative fluorescence units (RFUs). Mean values and
SD were calculated from triplicates. Data represent one of three in-
dependently done experiments. Student’s t-test for unpaired hetero-
scedastic samples was used for statistical analysis. #P < .05, *P <
.01, **P< .001, ***P < .0001. Bz indicates bortezomib; Co, control
(PBS-treated); Vp, verapamil.
Figure W3. The reduced viability of verapamil-treated cellswas slightly
reverted by the autophagy inhibitor 3-methyladenine. JK-6L cells
were treated with 10 nM bortezomib and 70 μM verapamil or the
combination of both inhibitors in the absence or presence of 1 mM
3-methyladenine for 16 hours. (A) Cells were incubated with the vital
dyeAlamarBlue. The absorbance (OD)wasmeasuredusing a spectro-
photometer. Only relevant significance values are depicted. (B) The
diagram shows the percentages of viable (annexin V–FITCnegative/
propidium iodidenegative), apoptotic (annexin V–FITCpositive/propidium
iodidenegative), and necrotic/late apoptotic (annexin V–FITCpositive/
propidium iodidepositive) cells, analyzed by flow cytometry. Mean val-
ues and SD were calculated from triplicates. Data represent one of
three independently done experiments. Student’s t-test for unpaired
heteroscedastic samples was used for statistical analysis. #P < .05,
*P< .01, **P< .001, ***P< .0001. 3-MA indicates 3-methyladenine;
AxV, annexin V–FITC; Bz, bortezomib; Co, control (H2O-treated); PI,
propidium iodide; Vp, verapamil.
Figure W4. Bortezomib together with verapamil enhanced the cyto-
toxic activity toward bortezomib-resistant JK-6L cells. JK-6L cells
were cultured during three months with 10 nM bortezomib to estab-
lish bortezomib-resistant cells. Nonresistant and resistant JK-6L cells
were treated with 10 nM bortezomib and 70 μM verapamil or the
combination of both inhibitors for 16 hours. The diagram shows
the percentages of dead (annexin V–FITCpositive) cells analyzed by
flow cytometry. Mean values and SD were calculated from tripli-
cates. Data represent one of three independently done experiments.
Only relevant significance values are depicted. Student’s t-test for
unpaired heteroscedastic samples was used for statistical analysis.
#P< .05, *P< .01, **P< .001, ***P< .0001. AxV indicates annexin
V–FITC; Bz, bortezomib; Co, control (PBS-treated); Vp, verapamil.
